4-[[2-chloro-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl]methyl]benzamide | 1079083-52-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[[2-chloro-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl]methyl]benzamide
• CAS: 1079083-52-5
• 化学式: C₂₀H₂₂ClNO₆
• 分子量: 407.851
• InChiKey: NOHPMQDMMMBVEF-FQBWVUSXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  133
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[[2-chloro-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl]methyl]benzamide 在 borane tetrahydrofuran 作用下， 以52%的产率得到(2S,3R,4R,5S,6R)-2-(3-(4-(aminomethyl)benzyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
  参考文献：
  名称：

  Design and synthesis of fluorescent SGLT2 inhibitors

  摘要：

  The design and synthesis of the first fluorophore-conjugated SGLT2 inhibitors is described. The mode of linking the fluorophore to the SGLT2 pharmacophore was found to be crucial in achieving optimum potency. Superior potency to phlorizin was provided by examples containing TAMRA, BODIPY, Cy3B and NBD fluorophores. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.036
• 作为产物：
  描述：

  methyl 4-(2-chloro-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)benzoate 在 氨 作用下， 以 甲醇 为溶剂， 以77%的产率得到4-[[2-chloro-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl]methyl]benzamide
  参考文献：
  名称：

  Design and synthesis of fluorescent SGLT2 inhibitors

  摘要：

  The design and synthesis of the first fluorophore-conjugated SGLT2 inhibitors is described. The mode of linking the fluorophore to the SGLT2 pharmacophore was found to be crucial in achieving optimum potency. Superior potency to phlorizin was provided by examples containing TAMRA, BODIPY, Cy3B and NBD fluorophores. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.036

文献信息

• C-Aryl glucosides substituted at the 4′-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
  作者：Baihua Xu、Yan Feng、Huawei Cheng、Yanli Song、Binhua Lv、Yuelin Wu、Congna Wang、Shengbin Li、Min Xu、Jiyan Du、Kun Peng、Jiajia Dong、Wenbin Zhang、Ting Zhang、Liangcheng Zhu、Haifeng Ding、Zelin Sheng、Ajith Welihinda、Jacques Y. Roberge、Brian Seed、Yuanwei Chen

  DOI：10.1016/j.bmcl.2011.06.032

  日期：2011.8

  Introduction of alkyl or alkoxy substituents at the 4′-position was found to improve SGLT2 potency, whereas introduction of a hydrophilic group at this position was deleterious. Compounds with alkoxy-, cycloalkoxy- or cycloalkenyloxy-ethoxy scaffolds exhibited good inhibitory activity and high selectivity toward SGLT2. Selected compounds were investigated for in vivo efficacy.

  已经合成了一系列在远端芳基环的4'-位置具有各种取代基的C-芳基葡糖苷，并评估了其对hSGLT1和hSGLT2的抑制作用。发现在4'-位置处引入烷基或烷氧基取代基可提高SGLT2的效力，而在该位置处引入亲水性基团是有害的。具有烷氧基-，环烷氧基-或环烯氧基-乙氧基支架的化合物表现出良好的抑制活性和对SGLT2的高选择性。研究了所选化合物的体内功效。